Polygalaxanthone III

• Description :

  Polygalaxanthone III is extracted from polygala tenuifolia wild, has inhibitory effect towards CYP450 enzyme. Polygalaxanthone III inhibits chlorzoxazone 6-hydroxylation catalyzed by CYP2E1 with an IC50 of 50.56 μM[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Cytochrome P450

• Type :

  Natural Products

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/polygalaxanthone-iii.html

• Purity :

  99.28

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  COC1=C(O)C=C(OC(C=C(O)C([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3OC[C@@](CO)(O)[C@H]3O)O2)=C4O)=C4C5=O)C5=C1

• Molecular Formula :

  C25H28O15

• Molecular Weight :

  568.48

• Precautions :

  H302

• References & Citations :

  [1]Li ZL, et al. Effect of oligosaccharide esters and polygalaxanthone Ill from Polygala tenuifolia willd towards cytochrome P450. Zhongguo Zhong Yao Za Zhi. 2014 Nov;39 (22) :4459-63.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Natural Products

• Clinical Information :

  No Development Reported

• Isoform :

  CYP2

• CAS Number :

  [162857-78-5]